Harvard: AI might be an answer to healthcare red tape

Artificial intelligence may help stop the “downward spiral in productivity” in the U.S. healthcare system, which has been plagued by labor-intensive, inefficient administrative tasks, according to an article in the Harvard Business Review.

AI tools capable of processing vast amounts of data and making real-time recommendations could greatly reduce the administrative burdens in the healthcare system––and save money to boot. According to the article, about one-third of the $3 trillion annual costs of the U.S. healthcare system are administrative and operational inefficiencies.

Unlike the “Herculean effort” of adopting electronic health records, adopting AI is different.

“Where EHRs required billions of dollars in investment and multi-year commitments from health systems, AI is more about targeted solutions,” wrote Minoo Javanmardian, PhD, partner of health and life sciences at Oliver Wyman Health; and Aditya Lingampally, principal of health and life sciences at Oliver Wyman Health. “It involves productivity improvements made in increments by individual organizations without the prerequisite collaboration and standardization across health care players required with EHR adoption.”

Specifically, AI is enabling:

  • Faster hospital bed assignments
  • Easier and improved documentation
  • Automated fraud detection

As AI continues to be adopted into the healthcare space, providers can expect more capabilities to ease inefficiencies, improve care and reduce costs.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.